Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
PCRX 
Pacira BioSciences, Inc. (PCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: PCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $29.71
1 Year Target Price $29.71
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.61% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio 50.06 | 1Y Target Price 29.71 |
Price to earnings Ratio 50.06 | 1Y Target Price 29.71 | ||
Volume (30-day avg) 6 | Beta 0.23 | 52 Weeks Range 19.84 - 27.64 | Updated Date 01/9/2026 |
52 Weeks Range 19.84 - 27.64 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.99% | Operating Margin (TTM) 7.33% |
Management Effectiveness
Return on Assets (TTM) 2.89% | Return on Equity (TTM) 2.9% |
Valuation
Trailing PE 50.06 | Forward PE 7.48 | Enterprise Value 1298387575 | Price to Sales(TTM) 1.41 |
Enterprise Value 1298387575 | Price to Sales(TTM) 1.41 | ||
Enterprise Value to Revenue 1.81 | Enterprise Value to EBITDA 8.78 | Shares Outstanding 41100000 | Shares Floating 42295506 |
Shares Outstanding 41100000 | Shares Floating 42295506 | ||
Percent Insiders 1.88 | Percent Institutions 113.96 |
Upturn AI SWOT
Pacira BioSciences, Inc.
Company Overview
History and Background
Pacira BioSciences, Inc. (Nasdaq: PCRX) was founded in 1997. Initially focused on developing novel drug delivery systems, the company's trajectory shifted significantly with the development and commercialization of EXPAREL (liposomal bupivacaine), a long-acting local anesthetic. This marked a pivotal moment, transforming Pacira into a leader in non-opioid pain management solutions.
Core Business Areas
- Non-Opioid Pain Management Solutions: Pacira's primary focus is on developing and commercializing innovative non-opioid analgesic products designed to address unmet needs in acute and chronic pain management. This segment is driven by its flagship product, EXPAREL, and the pursuit of other novel pain therapies.
- Infectious Disease Solutions: More recently, Pacira has expanded into the infectious disease space with the acquisition of the Depo-Medrol franchise, which includes Depo-Medrol and Depo-Cyt, offering anti-inflammatory and anti-cancer treatments.
Leadership and Structure
Pacira BioSciences, Inc. is led by a seasoned executive team with expertise in pharmaceuticals, commercialization, and research and development. The company operates under a typical corporate structure with distinct departments for R&D, Commercial Operations, Manufacturing, and Finance.
Top Products and Market Share
Key Offerings
- EXPAREL (liposomal bupivacaine): EXPAREL is a multi-use, long-acting local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. It is also indicated for interscalene brachial plexus nerve block to produce postsurgical analgesia. Competitors include other local anesthetics like bupivacaine, ropivacaine, and lidocaine, as well as other multimodal pain management strategies. While specific market share data for EXPAREL is proprietary, it holds a significant position in the postsurgical analgesia market, particularly for patients seeking alternatives to opioids. Revenue from EXPAREL forms the substantial majority of Pacira's revenue.
- Depo-Medrol (methylprednisolone acetate): Depo-Medrol is a corticosteroid used for its anti-inflammatory and immunosuppressive properties in various conditions, including joint pain, asthma, and certain allergic reactions. Its companion product, Depo-Cyt, is indicated for palliative treatment of localized phenomena associated with malignant neuro-epithelial tumors. Competitors include other injectable corticosteroids like Kenalog and various oral corticosteroids. Pacira acquired this franchise to broaden its therapeutic offerings beyond pain management.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the pain management and infectious disease segments, is characterized by high R&D costs, stringent regulatory oversight, and a competitive landscape driven by innovation and market access. The opioid crisis has created a strong demand for effective non-opioid pain management alternatives, presenting a significant market opportunity. The infectious disease market is vast and driven by the need for novel treatments and preventative measures.
Positioning
Pacira BioSciences is well-positioned as a leader in the non-opioid pain management space, driven by the success of EXPAREL. Its focus on innovative drug delivery systems and its commitment to addressing the opioid crisis provide a strong competitive advantage. The expansion into infectious diseases with acquired products diversifies its portfolio and market reach.
Total Addressable Market (TAM)
The TAM for pain management is substantial, estimated in the tens of billions of dollars globally, with the non-opioid segment showing significant growth potential. The infectious disease market is even larger, representing hundreds of billions of dollars. Pacira, with EXPAREL, targets a significant portion of the postsurgical and acute pain market, and with its acquired products, addresses broader therapeutic areas within pain and infectious diseases.
Upturn SWOT Analysis
Strengths
- Strong market leadership in non-opioid pain management with EXPAREL.
- Proprietary drug delivery technology.
- Established commercial infrastructure and sales force.
- Growing revenue stream from EXPAREL.
- Diversification into infectious disease solutions.
Weaknesses
- Heavy reliance on a single primary product (EXPAREL) for a significant portion of revenue.
- High R&D investment required for new product development.
- Potential for generic competition in the future for EXPAREL.
- Complex reimbursement landscape for new pain management therapies.
Opportunities
- Expansion of EXPAREL indications and usage in new surgical procedures.
- Development of next-generation non-opioid pain therapies.
- Leveraging acquired infectious disease products for market growth.
- Geographic expansion of EXPAREL and other products.
- Strategic partnerships and collaborations.
Threats
- Intensifying competition from other pharmaceutical companies developing non-opioid pain solutions.
- Changes in healthcare policy and reimbursement rates.
- Regulatory hurdles for new product approvals.
- Unforeseen side effects or safety concerns with existing or new products.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- AbbVie Inc. (ABBV)
- Merck & Co., Inc. (MRK)
- Johnson & Johnson (JNJ)
Competitive Landscape
Pacira's advantage lies in its specialization and leadership in non-opioid pain management with EXPAREL, offering a unique, long-acting formulation. Competitors like Pfizer, AbbVie, Merck, and J&J are large, diversified pharmaceutical companies with broad portfolios, significant R&D budgets, and established market access. While they may offer other pain relief products or broad therapeutic solutions, Pacira's focused strategy in non-opioid pain can be a significant differentiator. However, their scale and resources allow them to compete aggressively across multiple fronts.
Major Acquisitions
Depo-Medrol franchise (Depo-Medrol and Depo-Cyt)
- Year: 2023
- Acquisition Price (USD millions): 250
- Strategic Rationale: To diversify Pacira's product portfolio beyond pain management and enter the established injectable corticosteroid and palliative care markets, leveraging its commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Pacira has experienced significant growth since the launch and widespread adoption of EXPAREL, transitioning from a development-stage company to a commercial-stage leader in its niche. Its revenue and market presence have steadily increased over the past decade.
Future Projections: Future growth is projected to be driven by continued penetration of EXPAREL into various surgical settings, potential expansion of its indications, and the successful integration and commercialization of its acquired product lines. Analyst consensus typically projects continued revenue growth and improving profitability.
Recent Initiatives: Recent initiatives include the acquisition of the Depo-Medrol franchise to broaden its portfolio, ongoing efforts to expand EXPAREL's label and market reach, and continued investment in its R&D pipeline for novel pain management and other therapeutic areas.
Summary
Pacira BioSciences, Inc. is a strong player in the non-opioid pain management market, primarily driven by the success of its flagship product, EXPAREL. The company benefits from a focused strategy, proprietary technology, and a growing demand for opioid alternatives. Recent diversification into infectious diseases through acquisitions shows a commitment to broader market reach. Key areas to monitor include continued EXPAREL market penetration, R&D pipeline advancements, and the competitive landscape of large pharmaceutical players who also operate in pain management.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations (SEC Filings: 10-K, 10-Q)
- Financial news outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Pharmaceutical industry market research reports
- Analyst reports and consensus estimates
Disclaimers:
This information is provided for informational purposes only and does not constitute financial advice. Market share data and TAM figures are estimates and may vary depending on the source and methodology. Financial performance details are subject to change and should be verified through official company filings. Stock performance is historical and not indicative of future results. Investing in the stock market carries inherent risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacira BioSciences, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2011-02-03 | CEO & Director Mr. Frank D. Lee | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 788 | Website https://www.pacira.com |
Full time employees 788 | Website https://www.pacira.com | ||
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.